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Small inhibiting moleculeLarge scale screening of libraries consisting of natural and small molecules led to the identiﬁcation
of many small molecule inhibitors repressing Wnt/b-Catenin signaling. However, targeted synthesis
of novel Wnt pathway inhibitors has been rarely described. We developed a modular and expedient
way to create the aromatic ring systemwith an aliphatic ring in between. Our synthesis opens up the
possibility, in principle, to substitute all positions at the ring system with any desired substituent.
Here, we tested ﬁve different haloquinone analogs carrying methoxy- and hydroxy-groups at differ-
ent positions. Bona ﬁdeWnt activity assays in cell culture and in Xenopus embryos revealed that two
of these compounds act as potent inhibitors of aberrant activated Wnt/b-Catenin signaling.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Aberrant activation of the Wnt/b-Catenin signaling pathway is
involved in the formation of many different human cancers,
including colon carcinoma, melanoma and hepatocellular carci-
noma. The hallmark in Wnt-induced cancer formation is enhanced
b-Catenin driven transcription, with b-Catenin sitting piggyback on
a DNA bound HMG-box transcription factor of the Tcf/Lef family
(see also the wnt homepage at http://www.stanford.edu/group/
nusselab/cgi-bin/wnt/). In multicellular organisms the activation
of theWnt/b-Catenin signaling pathway is tightly regulated by sev-
eral extracellular antagonists, including dkk family members [1,2]
and secreted frizzled related proteins [3,4].
The correlation of aberrant Wnt signaling and cancer formation
has driven the search for novel Wnt pathway inhibitors, which
might serve as suitable tool in cancer therapeutics [5,6]. As puta-
tive novel chemotherapeutics, many small molecule inhibitors act-
ing at different sites of the Wnt/b-Catenin signaling pathway have
been identiﬁed over last years. Some of them, including PKF 118-
774 inhibit b-Catenin/Tcf interaction [7], others act as inhibitors
of tankyrase [8] or casein kinase 1a [9,10] or suppress like NSC
668036 pathway activation at the level of frizzled/disheveled[11]. Despite the fact that meanwhile numerous Wnt pathway
inhibitors have been described, a sophisticated chemical synthesis
pathway for inhibitor production, modiﬁcation and improvement
has not been reported so far. Instead, most of the small molecule
inhibitors have been identiﬁed in large scale screens with natural
or synthetic compounds. Our approach, instead, was to synthesize
Wnt pathway inhibitors de novo, a strategy which allows further
for lead optimization and Structure–Activity-Relationship (SAR)
studies simply by variation/addition of different functional groups.
We used PKF118-744 [7], also termed haloquinone, as model com-
pound and found an easy way to synthesize analogues with various
side chains and functional groups on its backbone. We tested ﬁve
of these novel compounds in two bona ﬁde Wnt activity assays,
SuperTopFlash (STF) reporter gene assays in cell culture and sec-
ondary axis assays in Xenopus embryos, and identiﬁed two of them
as potent Wnt pathway inhibitors.
2. Methods
2.1. Synthesis
The synthesis was performed as described in Fig. 1. The double
Friedel–Crafts acylation to synthesize phenanthrene-9,10-diones
was achieved under the following conditions. To the commer-
cially-available biaryl substrate (3,30-dimethoxy-1,10-biphenyl,
Fig. 1. Synthesis of novel Wnt pathway inhibitors. (A) Concise and highly modular
pathway to phenanthrene-9,10-diones from functionalized arenes via coupling and
double Friedel–Crafts acylation of the resulting biaryls. (B) This double Friedel–
Crafts acylation of symmetrical biaryls with oxalyl chloride was used to synthesize
the compounds RFC, RFD and RFE. Conditions: For RFD: Oxalyl chloride (1.2 equiv),
aluminium trichloride (1.2 equiv), CH2Cl2 (0.1 M), rt, 15 h. For RFC: Oxalyl chloride
(1.2 equiv), aluminium trichloride (1.2 equiv), triﬂic acid (1.2 equiv), CH2Cl2 (0.1 M),
rt, 15 h. For RFE: Oxalyl chloride (1.2 equiv), aluminium trichloride (1.2 equiv),
triﬂic acid (1.2 equiv), CH2Cl2 (0.1 M), rt, 15 h. or RFD-HY and RFC-HY: Boron
tribromide, CH2Cl2 0 C to rt, 12 h.
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sphere of argon was added aluminium trichloride (1.2 equiv), then
oxalyl chloride (1.2 equiv). The reaction mixtures were then stirred
at room temperature for 24 h. Following this time, the reactions
were worked up by washing the organic layer with an equivalent
volume of ice/sodium hydrogen carbonate, then water, then brine,
followed by chromatography on silica gel with ethyl acetate/cyclo-
hexane mixtures. The yields were as follows: RFC 20%; RFD 36%;
RFE 44%. Following this, treating RFC and RFD in dichloromethane
solutions with boron tribromide (3.0 equiv) at 0 C then room tem-
perature for 12 h yielded RFC-HY (73%) and RFD-HY (63%), respec-
tively. The identity of all isolated compounds was conﬁrmed by 1H
NMR, 13C NMR and high-resolution MS analysis.2.2. Reporter gene assays and Real-time PCR
Human embryonic kidney hek293 cells (ATCC CRL-1573) were
transfected with STF, CMV b-Galactosidase, XTcf-1 and constitutive
active b-Catenin as previously described [12]. 24 h after transfec-
tion the inhibitors solved in 1% DMSO were added in a ﬁnal con-
centration of 2.5 lM. Total RNA was extracted from SW480
(ATCC CCL-228) colorectal cancer cells (high pure RNA isolation
Kit, Roche) and used for gene expression analysis. 150 ng of total
RNA were used for cDNA synthesis with oligo (dT) primers and
MMLV reverse transcriptase. qRT-PCR was performed using
Rib36B4 primer as endogenous control (forw: 50-gaa ggc tgt ggt
gct gat gg-30, rev: 50-ccg gat atg agg cag cag-30 (61.8 C) and axin2
primer (fwd: 50-act gcc cac acg ata agg ag-30, rev: 50-ctg gct atg tct
ttg gac ca-30 (60.2 C) with SYBR Green Supermix in an icycler
(BIORAD).
2.3. Embryo manipulation
For secondary axis induction, 500 pg XTcf-1 mRNA solved in 1%
DMSO were injected into the marginal zone of both ventral blasto-
meres at the 4-cell stage. 0.5 pmol of the indicated inhibitors were
co-injected. Two to three days after injection the embryos were
scored for the appearance of a secondary body axis.
To determine the effect of the inhibitors on the expression of
endogenous Wnt target genes, 0.5 and 5 pmol of the inhibitors
were injected into one blastomere of two-cell stage embryos. As
lineage tracer we co-injected FITC–dextran. In neurula stages, the
embryos were sorted according to the ﬂuorescence signal into left
and right injected. At embryonic stage 28 (according to reference
[13]) embryos were ﬁxed in MEMFA and analyzed for the expres-
sion of en2 and XTcf-4 as described in [14]. Embryos were consid-
ered to show a reduced expression of these Wnt target genes when
either the area or the intensity of the signal was decreased on the
injected side compared to the uninjected control side.
3. Results
Based on the structure of haloquinone we developed a synthetic
reaction for easy production of structurally related compounds.
The putative synthetic route to murrayaquinone was required to
be extremely modular in nature, as the intention was to synthesize
a variety of substituted analogues for testing in Wnt sensitive as-
says. Initially, unaware of a 1912 precedent from Liebermann, we
speculated that the 1,2-diketo functionality might be conveniently
installed in one step by double-electrophilic aromatic substitution
upon biaryl substrates with an appropriate C2-synthon, e.g., oxalyl
chloride. These substrates are extremely facile to synthesize in a
modular sense via a variety of well-established transition-metal
catalyzed techniques. We reasoned that from a variety of function-
alized aryl species, both symmetrical and asymmetrical combina-
tions of arenes could be converted in just two steps to a large
variety of tricyclic core (phenanthrene-9,10-dione) products
(Fig. 1A). Phenanthrene-9,10-diones are found as the cores of
numerous biologically active natural products, and derivatives of
this motif are frequently the focus of medicinal chemistry pro-
grams [15]. Nonetheless, the existing synthetic methods towards
these compounds all suffer from severe practical drawbacks. Syn-
theses can be grouped into two categories, starting either from
phenanthrenes and involve the use of strong acids and oxidizing
agents, or by way of less direct synthetic intermediates, which typ-
ically feature numerous sequential steps [16–19]. We present
herein a simple and effective method for the synthesis of the phen-
anthrene-9,10-dione core derivatives.
For the synthesis of the phenanthrene-9,10-dione core, with a




Fig. 2. STF assays in hek293 cells revealed that two out of ﬁve of the novel compounds inhibit aberrant Wnt pathway activation in hek293 cells. (A) Constitutive active b-
Catenin S33A activates the Wnt-dependent STF promoter more than 700-fold, co-transfection with XTcf-1 leads to a 1400-fold activation. Basal promoter activity is set as 1.
(B) Structure of the novel putative Wnt pathway inhibitors. (C) 24 h after transfection and 24 h before analysis cells were treated with 2.5 lM inhibitor in 1% DMSO. The more
than 700-fold activation of basal promoter activity by b-Catenin was set as 1. Signiﬁcant inhibition of reporter gene activity (⁄P < 0.005) was seen in the presence of
haloquinone (Halo) and RFD. The other novel compounds did not signiﬁcantly inhibit STF (P > 0,02). (D) Adding the compounds to hyperactivated cells revealed that in
addition to haloquinone and RFD, RFD-HY also acts as a STF inhibitor. A, C and D show the mean values and standard errors of at least 8 independent transfections. (E) Relative
axin2 expression in SW480 cells. 16 h before lysis 2.5 lM inhibitor were added to the cell culture medium. The relative expression is normalized to untreated control cells.
Shown is the average and standard deviation of three independent experiments.
524 S. Halbedl et al. / FEBS Letters 587 (2013) 522–527multi-step sequences from phenanthrenes, typically via ene-enol
oxidation or cis-dihydroxylation followed by further oxidation
steps. One or both of these steps are typically performed under ex-
tremely harsh conditions, with multiple equivalents of toxic metalsand noxious oxidants, and high temperatures. Furthermore, these
conditions are unsuitable for the presence of many functional
groups and sensitive substituents, and thus not suitable for modu-
lar synthetic strategies. Sensing an opportunity for improvement of
S. Halbedl et al. / FEBS Letters 587 (2013) 522–527 525the synthetic options available to the chemist, we decided to ex-
plore the feasibility of the double Friedel–Crafts acylation reaction
with a variety of easily-accessed substrates (Fig. 1B). The symmet-
rical biaryl species (Fig. 1B) was commercially available and ex-
posed to oxalyl chloride under typical Friedel–Crafts conditions
[20], furnishing the corresponding phenanthrene-9,10-dione RFD
and RFC. Demethylation of these compounds with boron tribro-
mide easily gave the respective diphenolic products RFD-HY and
RFC-HY and the mono-a-demethylated derivative of RFC, termed
RFE. It is worth mentioning that starting with different symmetri-
cal biaryl species a great variety of different compounds can be
synthesized in a similar manner.
We started to test selected members of these novel compounds
in the STF assay in hek293 cells (Fig. 2). We used the above men-
tioned compounds RFD, RFD-HY, RFC, RFC-HY and RFE, respec-
tively. Similar to haloquinone (RF118-744), we expected that
some of the novel synthetic compounds also inhibit Wnt/b-Catenin
signaling at the level of transcription factor/co-activator binding.
Therefore we activated the STF promoter by co-transfection of
XTcf-1 and b-Catenin (Fig. 2A). While XTcf-1 activated the STF
about 40-fold, b-Catenin increased promoter activity almost 800-
fold, and co-transfection with b-Catenin and XTcf-1 resulted in a
1400-fold activation of the promoter. Adding the novel synthetic
inhibitor RFD in a ﬁnal concentration of 2.5 lM to the medium re-A
C
Fig. 3. RFD and RFD-HY suppress XTcf-1 induced secondary axis formation. 500 pg XTc
ectopic axis in almost 80 percent of the injected embryos. Co-injection of 0.5 pmol of RF
respectively. RFC and RFE have no effect. (A) Dorsal view of selected embryos. The ectopi
secondary axis. Shown are the mean values and standard errors of at least four independe
that RFD does not reduce the amounts of XTcf-1 protein. RIPA lysates corresponding to on
incubated with an anti Flag speciﬁc antibody recognizing the Flag-epitope of the tagged X
equal loading.sulted in signiﬁcant decrease of promoter activation. In b-Catenin-
stimulated cells this inhibition was similar to the inhibition by
2.5 lM haloquinone (Fig. 2C). Other compounds, including RFD-
HY and RFC displayed only weak and statistically insigniﬁcant inhi-
bition of STF. RFC-HY and RFE had no effect on the reporter
(Fig. 2C). Also in b-Catenin + XTcf-1 stimulated cells RFD was the
most potent inhibitor among the novel compounds (Fig. 2D). In
contrast to the b-Catenin – alone stimulated cells, the cells stimu-
lated simultaneously with XTcf-1 and b-Catenin revealed that RFD-
HY also signiﬁcantly blocks the activation of STF. However, both,
RFD and RFD-HY were less potent inhibitors than haloquinone
and RFD is more potent in this assay than RFD-HY. All other novel
compounds showed no effect. Thus, two out of ﬁve of the novel
compounds appear to block aberrantly activated Wnt signaling in
human cells. To test whether our inhibitors also suppress endoge-
nous Wnt target genes we analyzed axin2 expression in SW480
colorectal cancer cells (Fig. 2E). Here all tested compounds, includ-
ing RFC led to a decrease in axin2 expression.
We further tested whether the novel inhibitors can also block
aberrant Wnt signaling in whole organisms. Therefore we injected
500 pg XTcf-1 mRNA disolved in 1% DMSO into the marginal zone
of both ventral blastomeres of Xenopus 4-cell stage embryos to in-
duce in 77% of the injected embryos the formation of an ectopic
body axis (Fig. 3A and B). Co-injection of 0.5 pmol RFD-HY reducedB
f-1 mRNA injected into the marginal zone of both ventral blastomeres induced an
D and RFD-HY reduced the frequency of secondary axis formation to 40% and 60%,
c axis formation is best seen by the Y-shape of the neural tube. (B) Quantiﬁcation of
nt experiments. n = number of analyzed embryos. (C) Western Blot analysis revealed
e half embryo were separated on an 8% SDS–PAGE, transferred to nitrocellulose and
Tcf-1 protein. A parallel gel was stained with Coomassie brilliant blue (CBB) to verify
A B
DC
Fig. 4. RFD and RFD-HY suppress the expression of the Wnt target genes XTcf-4 and en2. 0.5 and 5 pmol of the indicated inhibitor were injected into the animal pole of one
blastomere at the two-cell stage. (A) XTcf-4 mRNA is located in the dorsal midbrain. Unilateral injection of 5 pmol RFD and RFD-HY, but not of RFC, RFE and FITC–dextran
results in reduced XTcf-4 expression at the injected side (marked by an asterisk). (B) Quantiﬁcation of the results. Shown is the percentage of embryos with reduced XTcf-4
expression following control injections or injections of 0.5 and 5 pmol of the indicated inhibitors. N: number of analyzed embryos. (C) en2 mRNA is located in the midbrain
hindbrain boundary. Unilateral injection of 5 pmol RFD and RFD-HY, but not of RFC, RFE and FITC–dextran results in reduced en2 expression at the injected side (marked by
an asterisk). (D) Quantiﬁcation of the results. Shown is the percentage of embryos with reduced en2 expression following control injections or incections of 0.5 and 5 pmol of
the indicated inhibitors. N: number of analyzed embryos.
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haloquinone (not shown) and RFD to 50%. This inhibition was not
due to reduced XTcf-1 translation, because protein levels of XTcf-
1 were independent of the presence of RFD (Fig. 3C). Interestingly,
the same compounds that failed to inhibit STF activation in hek293
cells also failed to inhibit aberrant Wnt pathway activation in in-
jected embryos (Fig. 3A and B).
Thus, two of the haloquinone analogues block the activated
Wnt/b-Catenin pathway downstream of b-Catenin in two indepen-
dent bona ﬁde Wnt activity assays. However, both the STF and ec-
topic axis assays, depend on an aberrantly activated pathway.
To ascertain whether the compounds are also capable to sup-
press endogenous Wnt/b-Catenin signaling in living animals we
analyzed the expression of the direct Wnt target genes XTcf-4
[21] and engrailed 2 (en2) [22] in the developing Xenopus brain.
While XTcf-4 is regulated directly by XTcf-1 [14,23], en2 is regu-
lated indirectly via the XTcf-1 target gene XTcf-4 [23,24].
When we injected our novel inhibitors into the animal hemi-
sphere of one blastomere of Xenopus two-cell stage embryos, we
observed that the expression of the direct XTcf-1 target gene
XTcf-4 was reduced by the same inhibitors which suppressed ecto-
pic Wnt pathway activation (Fig. 4A and B). The control injections
with 1% DMSO and the lineage tracer FITC–dextran revealed re-duced XTcf-4 expression at the injected site in less than 7% of
the injected embryos. This was similar to asymmetric XTcf-4
expression in untreated control embryos. Co-injection of 0.5 pmol
RFD and RFD-HY increased the frequency of XTcf-4 reduction to
approximately 22% of the injected embryos (Fig. 4A and B). Ten-
fold increase of the inhibitor dose increased the frequency of
XTcf-4 reduction by RFD to more than 40%. RFC was inactive and
RFE showed no dose dependency. Thus, RFD and RFD-HY reduced
endogenous XTcf-1 driven transcription.
Consistently, the expression of the Wnt target gene en2 was re-
duced by the same inhibitors, again in a dose-dependent manner.
The control injected embryos, again, showed an almost symmetri-
cal expression of en2. In less than 5% of the injected embryos, en2
expression was reduced (Fig. 4C and D). RFC did not induce any fur-
ther reduction. 0.5 pmol RFD, RFE and RFD-HY, instead, increased
the frequency of en2 reduction up to 15–29%. For RFE a ten-fold in-
crease of the dose did not accelerate the frequency of en2 reduc-
tion. Thus, the effect of this compound on en2 expression should
be considered as unspeciﬁc. RFD and RFD-HY, however reduced
en2 expression in a dose-dependent manner, for RFD-HY from
15% to 22% and for RFD from 19% to 37% (Fig. 4C and D).
Thus, two out of ﬁve of the novel inhibitors did indeed suppress
Wnt/b-Catenin signaling in all four assays.
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Based on the structure of the natural b-Catenin/Tcf inhibitor
PKF118-744 [7] we designed a strategy for the synthesis of puta-
tive novel inhibitors of Wnt regulated transcription. The modular
nature of the synthesis together with a platform for studying
Wnt pathway regulation now enables a directed function-based
synthesis of novel small inhibiting molecules. We tested ﬁve novel
compounds in different Wnt-activity assays and found that two of
them, RFD and RFD-HY, act as potent inhibitors. In general, a po-
tent inhibitor of Wnt/b-Catenin signaling should be effective in dif-
ferent Wnt assays. Blocking only STF activation in transfected
hek293 cells could also be solely a promoter or cell type speciﬁc ef-
fect. Similarly, blocking the expression of axin2 might also be due
to inhibition of other transcription factors regulating the expres-
sion of this Wnt target gene. Blocking secondary axis formation
might be caused by effects parallel or downstream of siamois,
and blocking expression of the brain speciﬁc Wnt target genes
XTcf-4 and en2 might be due to unspeciﬁc effects disturbing mid-
brain and mid/hindbrain development in general. Thus, only the
compounds RFD and RFD-HY, which impaired Wnt signaling in
all assays should be considered as inhibitors.
Comparing the structure of the active inhibitors RFD, RFD-HY
and haloquinone with the inactive compounds RFC, RFC-HY and
RFE it appears that it is not relevant whether the substituents at
the aromatic rings are hydroxy- or methoxy-groups. Also the 1-
oxy-ethyl residue at haloquinone is not necessary for its inhibitory
function, because both, RFD and RFD-HY lack this substituent. In-
stead, a symmetric ring system seems to be a prerequisite for po-
tent Wnt pathway inhibition. Interestingly, many of the known
inhibitors of b-Catenin driven transcription, including PKF115-
584, PKF222-815 and CGP049090 also feature a symmetric back-
bone [5,7]. In contrast, Wnt inhibitors blocking other components
of the Wnt/b-Catenin pathway do not show similar symmetries.
These include the commercially available porcupine inhibitors
IWP-2 to 4, the tankyrase inhibitor JW55 [8] and the GSK inhibitor
Bio [25]. This leads us to speculate that a small planar symmetrical
inhibitor might be optimal for inhibiting b-Catenin/Tcf driven tran-
scription. Further studies are required to show the structural basis
of the inhibitory effect of planar symmetric small molecules.
Interestingly, in developing embryos, doses of the inhibitor that
suppress ectopically activated Wnt/b-Catenin signaling also tend
to repress endogenous Wnt signaling. Indeed, 0.5 pmol of the
inhibitors moderately reduced the frequency of XTcf-1 induced
secondary axes and signiﬁcantly suppressed the expression of the
Wnt target genes XTcf-4 and en2. This result highlights a general
problem with small molecules inhibiting the Wnt/b-Catenin path-
way as therapeutics. The importance of this pathway for many
developmental processes, including axis induction, brain pattern-
ing, neural crest formation and limb development, make it likely
that whenever small molecule inhibitors of the Wnt/b-Catenin
pathway are used as therapeutics, it should be considered that they
will most likely have teratogenic effects. Our modular synthesis
platform for symmetric planar compounds allows the addition/
variation of functional groups, which might be used for targeting
the drug or for minimizing their travel through the placenta.
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